New Studies on Zebinix® Presented at Leading European Epilepsy Congress PR Newswire HATFIELD, England, October 3, 2012 HATFIELD, England, October 3, 2012 /PRNewswire/ -- Bial and Eisai today present information on new studies designed to increase ®the understanding of the use of Zebinix (eslicarbazepine acetate), a once- daily adjunctive therapy for adults with partial-onset seizures, with or without secondary generalisation, at the 10th European Congress on Epileptology (ECE) [1]in London. These new data will be important as the successful treatment of partial-onset seizures remains a challenge, and up to a third of people with epilepsy do not achieve freedom from seizures despite appropriate therapy with anti-epileptic [2]drugs. [3]Eslicarbazepine acetate in Partial-Onset Seizures study (EPOS) Launched in March 2012, the Eslicarbazepine acetate in Partial-Onset Seizures (EPOS) study design presented here aims to provide a better understanding of the use of eslicarbazepine acetate in a clinical practice setting. EPOS is a prospective, multicentre, open-label, non-interventional study of adults with partial-onset seizures insufficiently controlled by monotherapy anti-epileptic treatment. The goal is to recruit approximately 800 patients from over 200 centres in Denmark, France, Germany, Norway, Sweden and the UK. The study primary endpoint will be 6-month retention rate and other assessments will include seizure frequency, adverse events and quality of life.
Voir